566 related articles for article (PubMed ID: 30342750)
1. The challenges of checkpoint inhibition in the treatment of multiple myeloma.
Paul B; Kang S; Zheng Z; Kang Y
Cell Immunol; 2018 Dec; 334():87-98. PubMed ID: 30342750
[TBL] [Abstract][Full Text] [Related]
2. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
Chung C
Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibition in Myeloma: Opportunities and Challenges.
Costa F; Das R; Kini Bailur J; Dhodapkar K; Dhodapkar MV
Front Immunol; 2018; 9():2204. PubMed ID: 30319648
[TBL] [Abstract][Full Text] [Related]
4. Chimeric antigen receptor T cell therapies for multiple myeloma.
Wu C; Zhang L; Brockman QR; Zhan F; Chen L
J Hematol Oncol; 2019 Nov; 12(1):120. PubMed ID: 31752943
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
Podar K; Jager D
Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
[TBL] [Abstract][Full Text] [Related]
6. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors.
Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001
[TBL] [Abstract][Full Text] [Related]
7. Immune-based therapies in the management of multiple myeloma.
Zanwar S; Nandakumar B; Kumar S
Blood Cancer J; 2020 Aug; 10(8):84. PubMed ID: 32829378
[TBL] [Abstract][Full Text] [Related]
8. Immunopathogenesis and immunotherapy of multiple myeloma.
Tamura H
Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors for the treatment of myeloma: novel investigational options.
Le Calvez B; Moreau P; Touzeau C
Expert Opin Investig Drugs; 2021 Sep; 30(9):965-973. PubMed ID: 34253136
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
Htut M
Curr Hematol Malig Rep; 2019 Feb; 14(1):1-10. PubMed ID: 30666505
[TBL] [Abstract][Full Text] [Related]
11. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
Cho SF; Anderson KC; Tai YT
Front Immunol; 2018; 9():1821. PubMed ID: 30147690
[TBL] [Abstract][Full Text] [Related]
12. New Strategies in Multiple Myeloma: Immunotherapy as a Novel Approach to Treat Patients with Multiple Myeloma.
Neri P; Bahlis NJ; Lonial S
Clin Cancer Res; 2016 Dec; 22(24):5959-5965. PubMed ID: 27797968
[TBL] [Abstract][Full Text] [Related]
13. Current developments in immunotherapy in the treatment of multiple myeloma.
Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M
Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma.
Castella M; Fernández de Larrea C; Martín-Antonio B
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30445802
[TBL] [Abstract][Full Text] [Related]
15. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
[TBL] [Abstract][Full Text] [Related]
16. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy of Lymphoma and Myeloma: Facts and Hopes.
Pianko MJ; Moskowitz AJ; Lesokhin AM
Clin Cancer Res; 2018 Mar; 24(5):1002-1010. PubMed ID: 28899972
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy in multiple myeloma: when, where, and for who?
Verkleij CPM; Korst CLBM; van de Donk NWCJ
Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
[TBL] [Abstract][Full Text] [Related]
19. Clinical Development of PD-1 Blockade in Hematologic Malignancies.
Pianko MJ; Goldberg AD; Lesokhin AM
Cancer J; 2018; 24(1):31-35. PubMed ID: 29360725
[TBL] [Abstract][Full Text] [Related]
20. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
